Evidence map›Paper›PMID 36270332›Full record

ArticleAnalytical biochemistry2023

Protein A-Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G.

Suman Nandy, Mary Crum, Katherine Wasden, Ulrich Strych, Atul Goyal, Vijay Maranholkar, William Mo, Binh Vu, Katerina Kourentzi, Richard C Willson

Open access · greenAbstract read
In one paragraph

Article in Analytical biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Suman NandyWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Mary CrumWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Katherine WasdenWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Ulrich StrychWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Atul GoyalWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Vijay MaranholkarDepartment of Biology and Biochemistry, University of Houston, Houston, TX, USA.
William MoWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Binh VuWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Katerina KourentziWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Richard C WillsonWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA; Department of Biology and Biochemistry, University of Houston, Houston, TX, USA; Escuela de Medicina y Ciencias de Salud, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico. Electronic address: willson@uh.edu.
University of Houston · US

Funding

Novel Point of Care assays for Urinary Diagnostics of NephritisR01AR072742 · NIAMS · UNIVERSITY OF HOUSTON · PI MOHAN, CHANDRA, WILLSON, RICHARD · 2017 to 2020
$1.3M
ACL HHS U01CK000512NCEZID CDC HHS U01 CK000512NIAMS NIH HHS R01 AR072742
6 · The paper itself

Abstract

Detection and quantification of antibodies, especially immunoglobulin G (IgG), is a cornerstone of ELISAs, many diagnostics, and the development of antibody-based drugs. Current state-of-the-art immunoassay techniques for antibody detection require species-specific secondary antibodies and carefully-controlled bioconjugations. Poor conjugation efficiency degrades assay performance and increases the risk of clinical false positives due to non-specific binding. We developed a generic, highly-sensitive platform for IgG quantification by fusing the IgG-Fc binding Z domain of Staphylococcal Protein A with the ultrabright bioluminescence reporter Nanoluc-luciferase (Nluc). We demonstrated the application of this fusion protein in a sandwich IgG detection immunoassay using surface-bound antigens to capture target IgG and protein A-Nanoluc fusion as the detector. We optimized the platform's sensitivity by incorporating multiple repeats of the Z domain into the fusion protein constructs. Using rabbit and mouse anti-SARS-CoV-2 Nucleoprotein IgGs as model analytes, we performed ELISAs in two different formats, either with SARS-CoV-2 Nucleoprotein as the capture antigen or with polyclonal chicken IgY as the capture antibody. Using standard laboratory equipment, the platform enabled the quantitation of antibody analytes at concentrations as low as 10 pg/mL (67 fM).

Indexed as

COVID-19Immunoglobulin GAnimalsAntibodies, ViralImmunoassayLuciferasesMiceNucleoproteinsRabbitsSARS-CoV-2Sensitivity and SpecificityStaphylococcal Protein AAntibodies, ViralImmunoglobulin GLuciferasesnanolucNucleoproteinsStaphylococcal Protein ABioluminescenceIgG detectionImmunoassayNanoluciferaseProtein ASARS-CoV-2 Nucleoprotein

Identifiers

PMID36270332
PMCPMC9826736
OpenAlexW4306757228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.